206265-92-1

Basic information

• Product Name: N-(3-(2-(2-(3-((tert-butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazolyl)pentanamide
• Synonyms: N-(3-(2-(2-(3-((tert-butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazolyl)pentanamide
• CAS NO: 206265-92-1
• Molecular Weight: 816.054
• Mol File: 206265-92-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-(3-(2-(2-(3-((tert-butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazolyl)pentanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(2-(2-(3-((tert-butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazolyl)pentanamide(206265-92-1)
• EPA Substance Registry System: N-(3-(2-(2-(3-((tert-butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazolyl)pentanamide(206265-92-1)

Safety Data

• Hazardous Substances Data: 206265-92-1(Hazardous Substances Data)

Upstream product

• 14660-52-7 ethyl 5-bromovalerate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4246-51-9 4,7,10-trioxa-1,13-diaminotridecane 
• 206265-90-9 5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazoyl)pentanoic acid 
• 194920-62-2 tert-butyl N-(3-{2-[2-(3-aminopropoxy)ethoxy]ethoxy}propyl)carbamate 
• 206265-82-9 ethyl 5-(5-(5-(4,6-diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetrazolyl)pentanoate 
• 141748-00-7 5-{1,1-dimethyl-5-[(4,6-diphenyl-2-pyridyl)oxy]pentyl}-[1H]-tetrazole 

Relevant articles and documents

Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci

In previous studies we demonstrated that lipophilic 99mTc- labeled LTB4 antagonist 1 (RP517) accumulated in infectious foci in rabbits, but hepatobiliary clearance hampered imaging of abdominal lesions. We now report the use of cyste

Radiopharmaceuticals for imaging infection and inflammation

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and

Radiopharmaceuticals for imaging infection and inflammation

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and